Autologous Bone Marrow Transplantation - Blog Science Connections

More documents

Recommendations

Info

Optimum Timing of Autologous Bone Marrow Transplantation for Patients With Large B-Cell Lymphoma Subhash C. Gulati, Brenda Shank, Pat Black, James Yopp, Benjamin Koziner, David Straus, Hugo Castro-Malaspina, Isabel Cunningham, Morton Coleman, Jens Atzpodlen, Kee Shum, Jon Kwon, Chihiro Shimazaki, O. Michael Colvin, Zvi Fuks, Richard O'Reilly, and Bayard Clarkson Recent combination chemotherapy protocols have improved the survival rates for patients with non-Hodgkin's lymphoma. Extended long-term disease-free survival was first reported with MOPP (mechlorethamine, Oncovin [vincristine], procarbazine, prednisone) or C-MOPP (MOPP plus cyclophosphamide) (1). Subsequently, most protocols have used regimens that contain Adriamycin (doxorubicin), Cytoxan (cyclophosphamide), and vincristine (CHOP, CHOP-Bleo, BACOP, ACOMLA). These protocols have produced a complete remission (CR) incidence of 40-70%, but a significant number of patients relapse (2-6). Newer regimens, including ProMACE-MOPP (7), COP-BLAM (8,9), M-BACOD (10), m-BACOD (11), and MACOP-B (methotrexate + Leucovorin rescue, Adriamycin [doxorubicin]) (12), have 279
Page 1:
Autologous Bone Marrow Transplantat
Page 5 and 6:
Page 7:
To our colleagues, Drs. R. Lee Clar
Page 10 and 11:
via ABMT Autologous Bone Marrow Tra
Page 12 and 13:
X ABMT Pharmacological Manipulation
Page 14 and 15:
XII ABMT C. INTERNATIONAL RANDOMIZE
Page 16 and 17:
xiu ABMT Session IV - Breast Cancer
Page 18 and 19:
xui ABMT Panel Discussion: Session
Page 20 and 21:
xuiii ABMT Effect of Interleukin 2
Page 23:
Acknowledgments The publication of
Page 27 and 28:
Page 29 and 30:
AML in First Remission 5 performed
Page 31:
AML in First Remission 7 than 50% o
Page 34 and 35:
10 BAVC + ABMT in Patients With AML
Page 36 and 37:
BAVC + ABMT in Patients With AML in
Page 38 and 39:
14 BAVC + ABMTin Patients With AML
Page 40 and 41:
16 Purged ABMT in CR of Acute Leuke
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
24 First-Remission Autograft forAML
Page 50 and 51:
Page 52 and 53:
Page 55 and 56:
Page 57:
Transplantation in CRI AML 33 DISCU
Page 60 and 61:
36 ABMT in ALL compared the results
Page 62 and 63:
38 ABMT in ALL were administered un
Page 64 and 65:
40 ABMT in ALL CR1 patients receive
Page 66 and 67:
42 ABMT in ALL 19. Rizzoli V, Mango
Page 68 and 69:
44 ABMTin CRI program in CR1 is the
Page 70 and 71:
46 ABMTin CRI RESULTS The AML inves
Page 73 and 74:
Leukemia: First Remission K A. Dick
Page 75 and 76:
Panel Discussion: Session IA 51 DR.
Page 77:
IB. Clinical Studies in Second- or
Page 80 and 81:
56 ABMTIn CR2 RESULTS OF VARIOUS TR
Page 82 and 83:
58 ABMTIn CR2 antibodies; for non-T
Page 84 and 85:
60 ABMT in Acute Nonlymphocytic Leu
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
70 ABMT in AML With Monoclonal Anti
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
80 Mafosfamide Purging in Leukemia
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 113 and 114:
Page 115 and 116:
ABMT in CR2 Pediatric ALL 91 follow
Page 117 and 118:
Ex Vivo Use of Monoclonal Antibodie
Page 119 and 120:
Ex Vivo Marrow Purging 95 Table 1.
Page 121 and 122:
De Viuo Marrow Purging 97 WBC-f- AN
Page 123 and 124:
Conditioning Regimens Before Bone M
Page 125 and 126:
Conditioning Regimens in AML 101 Le
Page 127:
Conditioning Regimens in AML 103 co
Page 130 and 131:
106 Double (Jnpurged ABMT in Leukem
Page 132 and 133:
108 Double Unpurged ABMT in Leukemi
Page 134 and 135:
770 Double (Jnpurged ABMT in Leukem
Page 136 and 137:
7/2 Double Autografting in Acute Le
Page 138 and 139:
114 Double Autografting in Acute Le
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
120 Recovery After 4-Hydroperoxycyc
Page 146 and 147:
122 Recovery After 4-Hydroperoxycyc
Page 149 and 150:
Page 151 and 152:
Panel Discussion: Session IB 127 di
Page 153:
Panel Discussion: Session IB 129 tu
Page 157 and 158:
Magnetic Affinity Colloid Eliminati
Page 159 and 160:
Magnetic Separation of Marrow Cells
Page 161 and 162:
Page 163 and 164:
*r r- r» u. >>• O S ^ CO ai a> C
Page 165 and 166:
Page 167 and 168:
4-Hydroperoxycyclophosphamide and V
Page 169 and 170:
Chemopurging 145 incubation, the ce
Page 171 and 172:
Chemopurging 147 To date, four pati
Page 173 and 174:
Chemopurging 149 4-HC + VCR IC75 AM
Page 175 and 176:
Decontaminating Bone Marrow With Me
Page 177 and 178:
Merocyanine 540 Marrow Decontaminat
Page 179 and 180:
Merocyanine 540 Marrow Decontaminat
Page 181 and 182:
CALLA-Negative Clonogenic Cultures
Page 183 and 184:
CALLA-Negatiœ Clonogenic BCell ALL
Page 185:
CALLA-Negative Clonogenic BCell ALL
Page 188 and 189:
164 Acetaldophosphamide Ex Vivo Che
Page 190 and 191:
766 Acetaldophosphamide Ex Vivo Che
Page 192 and 193:
168 Acetaldophosphamide Ex Viuo Che
Page 195 and 196:
Detecting Residual Disease in Bone
Page 197 and 198:
Page 199:
Page 202 and 203:
178 Pharmacological Manipulation an
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 211:
ID. Chronic Myelogenous Leukemia
Page 214 and 215:
190 CML Chronic Phase Autografting
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
196 CML Blast Crisis Autografting e
Page 223 and 224:
Autologous Transplantation of Phila
Page 225 and 226:
Autografting in Chronic Granulocyti
Page 227:
Autografting in Chronic Granulocyti
Page 230 and 231:
206 Panel Discussion: Session ID DR
Page 233 and 234:
Natural History of Relapsed Hodgkin
Page 235 and 236:
ABMT in Hodgkin's Disease 211 50%.
Page 237 and 238:
ABMTin Hodgkin, 's Disease 213 (62%
Page 239 and 240:
ABMT in Hodgkin's Disease 215 LLLLL
Page 241 and 242:
Updated Results of CBV and Autologo
Page 243 and 244:
CBV and ABMT in Hodgkin's Disease 2
Page 245:
CBV and ABMT in Hodgkin 's Disease
Page 248 and 249:
224 Chemotherapy and ABMT in Hodgki
Page 250 and 251:
226 Chemotherapy and ABMTin Hodgkin
Page 252 and 253: 228 Chemotherapy and ABMT in Hodgki
Page 254 and 255: 230 Chemotherapy and ABMT in Hodgki
Page 256 and 257: 232 ABMT for Advanced Hodgkin's Dis
Page 258 and 259: 234 ABMTfor Advanced Hodgkin's Dise
Page 261 and 262: Hodgkin's Disease J. O. Armitage an
Page 263 and 264: Panel Discussion: Session IIA 239 D
Page 265: IIB. Non-Hodgkin's Lymphoma
Page 268 and 269: 244 Salvage Chemotherapy for Lympho
Page 270 and 271: 246 Salvage Chemotherapy for Lympho
Page 273 and 274: Autologous Bone Marrow Transplantat
Page 275 and 276: ABMT in Burkitt's Lymphoma 251 Tabl
Page 277 and 278: ABMT in Burkitt's Lymphoma 253 medi
Page 279 and 280: ABMT in Burkitt's Lymphoma 255 Heal
Page 281 and 282: ABMT in Burkitt's Lymphoma 257 •
Page 283 and 284: ABMT in Burkitt's Lymphoma 259 init
Page 285: ABMT in Burkitt's Lymphoma 261 11.
Page 288 and 289: 264 Myeloma Biology and Therapy hig
Page 290 and 291: 266 Myeloma Biology and Therapy mon
Page 292 and 293: 265 Myeloma Biology and Therapy 5.
Page 294 and 295: 270 BMT in Relapsed Diffuse Large C
Page 300 and 301: 276 Transplantation for Malignant L
Page 304 and 305: 280 ABMT Timing in Lymphoma produce
Page 306 and 307: 0) O) .2 '55 o c O) o o Q. c o + +
Page 308 and 309: 284 ABMT Timing in Lymphoma ABMT on
Page 310 and 311: 286 ABMT Timing in Lymphoma abdomin
Page 312 and 313: « "5 a o « £ a> Z aT in O Q « O
Page 314 and 315: 290 ABMT Timing in Lymphoma Role of
Page 316 and 317: 292 ABMT Timing in Lymphoma inducti
Page 318 and 319: 294 ABMT Timing in Lymphoma Clift R
Page 321 and 322: Treatment Strategies for Advanced A
Page 323 and 324: Treatment Strategies for NHL 299 Su
Page 325 and 326: « E BS « oc c 4> E ai O c CD e 0)
Page 327 and 328: Treatment Strategies for NHL 303 So
Page 329 and 330: Treatment Strategies for NHL 305 pa
Page 331 and 332: Non-Hodgkin's Lymphoma S. Gulati an
Page 333: Panel Discussion: Session IIB 309 i
Page 337 and 338: An International Randomized Study o
Page 339 and 340: Proposed International Adult Lympho
Page 353 and 354:
Proposed International Adult Lympho
Page 355 and 356:
Page 357:
Page 360 and 361:
336 International NHL Trial THEORET
Page 362 and 363:
338 International NHL Trial RELAPSE
Page 364 and 365:
340 International NHL Trial ANALYSI
Page 366 and 367:
342 International NHL Trial The ste
Page 368 and 369:
344 Panel Discussion: Session IIC d
Page 371 and 372:
Chemoimmunoseparation of T Lymphoma
Page 373 and 374:
Chemoimmunoseparation of T Lymphoma
Page 375 and 376:
Using a Liquid Cell Culture Assay t
Page 377 and 378:
Burkitt's Lymphoma Purging Assay 35
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Comparative Efficiency of an Immuno
Page 385 and 386:
Purging Methods in Burkitt's Lympho
Page 387 and 388:
Purging Methods in Burkitt's Lympho
Page 389 and 390:
Susceptibility of Lymphoid Malignan
Page 391 and 392:
Leukemia Cell Sensitioity to Immuno
Page 393 and 394:
Leukemia Cell Sensitivity to Immuno
Page 395 and 396:
Lymphoma: Purging and Detecting K.
Page 397:
III. Neuroblastoma
Page 400 and 401:
376 ABMT for Neuroblastoma TOXICITY
Page 402 and 403:
378 ABMT for Neuroblastoma 100 Befo
Page 404 and 405:
380 ABMTfor Neuroblastoma modificat
Page 406 and 407:
382 ABMTfor Neuroblastoma Naval Med
Page 408 and 409:
384 ABMT in Metastatic Neuroblastom
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 417 and 418:
High-Dose Therapy and Unpurged Bone
Page 419 and 420:
Unpurged ABMTfor Neuroblastoma 395
Page 421 and 422:
(Jnpurged ABMT for Neuroblastoma 39
Page 423:
Unpurged ABMT for Neuroblastoma 399
Page 426 and 427:
402 High-Dose Melphalan in Neurobla
Page 428 and 429:
404 High-Dose Melphalan in Neurobla
Page 431 and 432:
Bone Marrow Transplantation in an C
Page 433 and 434:
ABMT in 65 Patients With Neuroblast
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
ABMTin 65 Patients With Neuroblasto
Page 441:
ABMTin 65 Patients With Neuroblasto
Page 444 and 445:
420 ABMT in Neuroblastoma Group 2
Page 446 and 447:
422 ABMT in Neuroblastoma RESULTS A
Page 449 and 450:
Transplantation for Neuroblastoma U
Page 451 and 452:
Purged Marrow Engraftment in Neurob
Page 453 and 454:
Page 455:
Page 458 and 459:
s o o o i o i - w n . t t i s T - T
Page 460 and 461:
436 Digital Image Analysis System a
Page 462 and 463:
438 Digital Image Analysis System T
Page 464 and 465:
440 Digital Image Analysis System u
Page 467 and 468:
Eliminating Burkitt's Cells From Ex
Page 469 and 470:
Immunomagnetic Purging ofBurkitt's
Page 471 and 472:
Immunomagnetic Purging ofBurkitt's
Page 473 and 474:
Neuroblastoma T. Philip and C. P. R
Page 475 and 476:
Panel Discussion: Session 111 451 w
Page 477:
IV. Breast Cancer
Page 480 and 481:
456 High-Dose Chemotherapy and ABMT
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 489 and 490:
Strategies in the Treatment of Brea
Page 491 and 492:
Treatment Strategies in Breast Canc
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Phase I and II Studies of High-Dose
Page 501 and 502:
a « O 75 o c Ü co s g c .2 — o
Page 503 and 504:
+ O CM CD CM CO CO O O CM O CM CM 8
Page 505 and 506:
High-Dose Chemotherapy and Autologo
Page 507 and 508:
High-Dose Therapy and ABMT in Breas
Page 509 and 510:
Immunodetection of Breast Carcinoma
Page 511:
Immunodetection of Breast Carcinoma
Page 514 and 515:
490 ABMTfor Breast Cancer initial s
Page 516 and 517:
492 ABMT for Breast Cancer agent gr
Page 518 and 519:
494 ABMT for Breast Cancer approach
Page 521 and 522:
Detection of Occult Breast Cancer C
Page 523 and 524:
Occult Breast Cancer Cells in Marro
Page 525 and 526:
Occult Breast Cancer Cells in Marro
Page 527 and 528:
Breast Cancer E. Frei III and R. Ba
Page 529 and 530:
Panel Discussion: Session IV 505 DR
Page 531:
V. Lung Cancer
Page 534 and 535:
570 Tumor Cell Detection MATERIAL A
Page 536 and 537:
512 Tumor Cell Detection Table 3. I
Page 539 and 540:
High-Dose Etoposide and Cisplatin W
Page 541 and 542:
Etoposide and Cisplatin for Lung Ca
Page 543 and 544:
Page 545:
Page 548 and 549:
524 Panel Discussion: Session V to
Page 550 and 551:
526 Panel Discussion: Session V sma
Page 553:
VI. Melanoma/Sarcoma/Carcinoma
Page 556 and 557:
532 ABMT in Melanoma chemotherapy a
Page 558 and 559:
534 ABMT in Melanoma Table 2. Effec
Page 560 and 561:
536 ABMT in Melanoma with either si
Page 562 and 563:
538 Panel Discussion: Session VI ca
Page 564 and 565:
540 Panel Discussion: Session VI sa
Page 567 and 568:
Intensive Monochemotherapy With Car
Page 569 and 570:
Carmustine and ABMTfor Malignant Gl
Page 571:
Carmustine andABMTfor Malignant Gli
Page 574 and 575:
550 High-Dose Carmustine and Transp
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
558 High-Dose Therapy of CHS Glioma
Page 584 and 585:
Page 586 and 587:
Page 589 and 590:
Brain Cancer S. Wolff and G. Herzig
Page 591:
Panel Discussion: Session VII 567 D
Page 595 and 596:
Intensification Regimens for Autolo
Page 597 and 598:
Clinical Intensification Regimens f
Page 599 and 600:
c « O) o in CM -r 1 •«t 00 i -
Page 601 and 602:
Page 603:
Page 606 and 607:
582 Busulfan + Cyclophosphamide in
Page 608 and 609:
Busulfan + Cyclophosphamide in Chil
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
590 Intensive use of Carmustine Pul
Page 617 and 618:
A Phase II Study of a New Cytoreduc
Page 619 and 620:
BEAM: Cytoreductiue Regimen for Lym
Page 621 and 622:
BEAM: Cytoreductiue Regimen for Lym
Page 623 and 624:
BEAM: Cytoreductlue Regimen for Lym
Page 625 and 626:
Total Body Irradiation, High-Dose C
Page 627 and 628:
Total Body Irradiation, Cytarabine,
Page 629 and 630:
New Regimens K. Antman and M. Syman
Page 631:
IX. Supportive Therapy
Page 634 and 635:
670 Herpesvirus Infections Table 1.
Page 636 and 637:
612 Herpesvirus Infections Table 3.
Page 639 and 640:
Autologous Blood Stem Cell Transpla
Page 641 and 642:
Peripheral Stem Cell Transplantatio
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
a c CO TO O O S E => CO "O CO i- t
Page 651 and 652:
3 w •o « C C o ü ü CD < , o E
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Toxic Deaths After Autologous Bone
Page 659 and 660:
Toxic Deaths in ABMT 635 RESULTS Fi
Page 661 and 662:
Toxic Deaths in ABMT 63 7 Patient/
Page 663 and 664:
Infectious Complications of Autolog
Page 665 and 666:
Infectious Complications of ABMT Ta
Page 667 and 668:
Infectious Complications ofABMT 643
Page 669:
Infectious Complications ofABMT 645
Page 672 and 673:
648 Infections in ABMT MATERIAL AND
Page 674 and 675:
650 Infections in ABMT Category Tab
Page 676 and 677:
652 Infections in ABMT been found,
Page 678 and 679:
654 Antibiotics in Cancer Patients
Page 680 and 681:
656 Antibiotics in Cancer Patients
Page 683 and 684:
The Empiric Use of Amphotericin B f
Page 685 and 686:
Amphotericin B for Neutropenie Feue
Page 687 and 688:
Amphotericin B for Neutropenie Feve
Page 689 and 690:
The Role of Intravenous Immune Glob
Page 691 and 692:
Mg in ABMT 667 broken down; antigen
Page 693 and 694:
The Possible Therapeutic Value of N
Page 695 and 696:
Natural Killer Cells and Transplant
Page 697:
Natural Killer Cells and Transplant
Page 700:
676 Transplantation of Circulating
Page 703:
Transplantation of Circulating Stem
Page 706 and 707:
682 Peripheral Stem Cell Transplant
Page 708 and 709:
684 Peripheral Stem Cell Transplant
Page 711 and 712:
Autologous Transplantation Using Pe
Page 713 and 714:
Peripheral Blood Stem Cell Transpla
Page 715 and 716:
Peripheral Blood Stem Cell Transpla
Page 717 and 718:
Bronchoscopic Examination and Bronc
Page 719 and 720:
Bronchoscopy in Marrow Transplantat
Page 721 and 722:
Effect of Interleukin 2 on T Lympho
Page 723 and 724:
c c 4) "5 Q. Ss •o 3 35 (A U «5
Page 725 and 726:
T Lymphocyte CFU After ABMT 701 Six
Page 727:
T Lymphocyte CFCJ After ABMT 703 no
Page 730 and 731:
706 Panel Discussion: Session IX se
Page 733 and 734:
Expression of Human Adenosine Deami
Page 735 and 736:
Human ADA in Monkeys 711 to the SAX
Page 737 and 738:
Human ADA in Monkeys 713 4 were nev
Page 739 and 740:
Human ADA in Monkeys 715 tuted marr
Page 741 and 742:
Electric Field-Mediated DNA Transfe
Page 743 and 744:
Page 745:
Page 748 and 749:
724 Aberrant Gene Expression in AML
Page 750 and 751:
Page 752 and 753:
Page 755 and 756:
Clonal Detection of Remission by Re
Page 757 and 758:
Clonal Detection of Remission 733 c
Page 759 and 760:
Clonal Detection of Remission 3 735
Page 761:
XI. Summary
Page 764 and 765:
740 Summary administration of the a
Page 766 and 767:
742 Summary particularly apparent i
Page 768 and 769:
744 Summary limited occurrence of t
Page 771 and 772:
Concluding Remarks Karel A. Dicke I
Page 773 and 774:
Contributors and Participants Zora
Page 775 and 776:
Contributors and Participants 751 M
Page 777 and 778:
Contributors and Participants 753 A
Page 779 and 780:
Contributors and Participants 755 R
Page 781 and 782:
Contributors and Participants 757 M
Page 783 and 784:
Contributors and Participants Leona
Page 785 and 786:
Contributors and Participants 761 L
Page 787 and 788:
Contributors and Participants 763 B
Page 789 and 790:
Contributors and Participants 765 J
Page 791 and 792:
Page 793 and 794:
Contributors and Participants 769 B
Page 795 and 796:
Contributors and Participants 771 G
Page 797 and 798:
Contributors and Participants 773 A
Page 799 and 800:
show all

Autologous Bone Marrow Transplantation - Blog Science Connections

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?